Cargando…

A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance

Pancreatic cancer is predominantly lethal, and is primarily treated using gemcitabine, with increasing resistance. Therefore, novel agents that increase tumor sensitivity to gemcitabine are needed. Histone deacetylase (HDAC) inhibitors are emerging therapeutic agents, since HDAC plays an important r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hee Seung, Park, Soo Been, Kim, Sun A, Kwon, Sool Ki, Cha, Hyunju, Lee, Do Young, Ro, Seonggu, Cho, Joong Myung, Song, Si Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278546/ https://www.ncbi.nlm.nih.gov/pubmed/28134290 http://dx.doi.org/10.1038/srep41615

Ejemplares similares

Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats
por: Lee, Eunjo, et al.
Publicado: (2016)

CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome
por: Suh, Sang Heon, et al.
Publicado: (2020)

Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease
por: Choi, Hong Sang, et al.
Publicado: (2018)

Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats
por: Bae, Eun Hui, et al.
Publicado: (2019)

CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway
por: Jung, Dawoon E., et al.
Publicado: (2017)

Epigenetic Modulation with HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells
por: Chun, Sung-Min, et al.
Publicado: (2015)

The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models
por: Kim, Young-Suk, et al.
Publicado: (2019)

Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production
por: Yoon, Ga-Eun, et al.
Publicado: (2019)

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment
por: Kim, Young-Dae, et al.
Publicado: (2020)

CG0009, a Novel Glycogen Synthase Kinase 3 Inhibitor, Induces Cell Death through Cyclin D1 Depletion in Breast Cancer Cells
por: Kim, Hyun Mi, et al.
Publicado: (2013)

Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction
por: Sharma, Chiranjeev, et al.
Publicado: (2019)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021)

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma
por: Lee, Dae-Hee, et al.
Publicado: (2015)

A Newly Identified CG301269 Improves Lipid and Glucose Metabolism Without Body Weight Gain Through Activation of Peroxisome Proliferator–Activated Receptor α and γ
por: Jeong, Hyun Woo, et al.
Publicado: (2011)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Internalization of Rat FSH and LH/CG Receptors by rec-eCG in CHO-K1 Cells
por: Park, Jong-Ju, et al.
Publicado: (2017)

Comparative gene expression profiling of mouse ovaries upon stimulation with natural equine chorionic gonadotropin (N-eCG) and tethered recombinant-eCG (R-eCG)
por: Min, Kwan-Sik, et al.
Publicado: (2020)

Specific Biological Activity of Equine Chorionic Gonadotropin (eCG) Glycosylation Sites in Cells Expressing Equine Luteinizing Hormone/CG (eLH/CG) Receptor
por: Byambaragchaa, Munkhzaya, et al.
Publicado: (2021)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

Attenuation of Rheumatoid Inflammation by Sodium Butyrate Through Reciprocal Targeting of HDAC2 in Osteoclasts and HDAC8 in T Cells
por: Kim, Da Som, et al.
Publicado: (2018)

Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
por: Min, Young Joo, et al.
Publicado: (2002)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
por: Wang, Xiaoguang, et al.
Publicado: (2020)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer
por: Moon, Do Chang, et al.
Publicado: (2016)

Gemcitabine-induced myositis in a diabetes mellitus patient on hemodialysis
por: Chun, June Young, et al.
Publicado: (2017)

Transforming Growth Factor β Inhibits MUC5AC Expression by Smad3/HDAC2 Complex Formation and NF-κB Deacetylation at K310 in NCI-H292 Cells
por: Lee, Su Ui, et al.
Publicado: (2021)

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer
por: Kim, Myeong Jin, et al.
Publicado: (2023)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

cg04448376, cg24387542, cg08548498, and cg14621323 as a Novel Signature to Predict Prognosis in Kidney Renal Papillary Cell Carcinoma
por: Wang, Ying-Lei, et al.
Publicado: (2020)

Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells
por: Cho, Jae Hee, et al.
Publicado: (2017)

1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) attenuates gemcitabine-induced neutrophil extravasation
por: Jeong, Jinseon, et al.
Publicado: (2019)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
por: Lee, Jeung Eun, et al.
Publicado: (2020)

The S1A protease family members CG10764 and CG4793 regulate cellular immunity in Drosophila
por: KR, Pooja, et al.
Publicado: (2021)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
por: Liva, Sophia G, et al.
Publicado: (2020)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Targeting HDAC6 to Overcome Autophagy-Promoted Anti-Cancer Drug Resistance
por: Jo, Hyein, et al.
Publicado: (2022)

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine
por: Liu, Wenchao, et al.
Publicado: (2019)

Biological functions of hCG and hCG-related molecules
por: Cole, Laurence A
Publicado: (2010)

Gemcitabine-Induced Hemolytic Uremic Syndrome in Pancreatic Cancer: A Case Report and Review of the Literature
por: Lee, Hye Won, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_231pdt0kc2bkurh4241pek4jq8